Abstract
The tyrosine kinase inhibitor STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of cancer. This review details the steps in the development of this agent and highlights why this drug has been so successful in the treatment of chronic myelogenous leukaemia. Future directions including the mechanisms and management of resistance and new therapeutic strategies are discussed. Finally, the literature supporting the use of STI571 in other malignancies, including solid tumors is briefly reviewed.
Keywords: Tyrosine Kinase Inhibitor, myelogenous leukaemia, Ph chromosome, allogeneic stem cell, optimal anti-leukemic effects, myelosuppression, CML blast crisis, Bcr-Abl associated leukemias, chronic myelomonocytic leukemic
Current Cancer Drug Targets
Title: The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
Volume: 1 Issue: 1
Author(s): Michael E. ODwyer and Brian J. Druker
Affiliation:
Keywords: Tyrosine Kinase Inhibitor, myelogenous leukaemia, Ph chromosome, allogeneic stem cell, optimal anti-leukemic effects, myelosuppression, CML blast crisis, Bcr-Abl associated leukemias, chronic myelomonocytic leukemic
Abstract: The tyrosine kinase inhibitor STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of cancer. This review details the steps in the development of this agent and highlights why this drug has been so successful in the treatment of chronic myelogenous leukaemia. Future directions including the mechanisms and management of resistance and new therapeutic strategies are discussed. Finally, the literature supporting the use of STI571 in other malignancies, including solid tumors is briefly reviewed.
Export Options
About this article
Cite this article as:
ODwyer E. Michael and Druker J. Brian, The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer, Current Cancer Drug Targets 2001; 1 (1) . https://dx.doi.org/10.2174/1568009013334250
DOI https://dx.doi.org/10.2174/1568009013334250 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets An Overview of Synthesis of Indole Alkaloids and Biological Activities of Secondary Metabolites Isolated from Hyrtios Species
Mini-Reviews in Medicinal Chemistry Biosafety of Onco-Retroviral Vectors
Current Gene Therapy NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications
Current Medicinal Chemistry The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry Domperidone and Long QT Syndrome
Current Drug Safety Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
Current Cancer Drug Targets Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry Chemical Genomic and Proteomic Methods for Determining Kinase Inhibitor Selectivity
Combinatorial Chemistry & High Throughput Screening Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry Editorial [Hot Topic: Novel and Emerging Drugs for Leukemias (Guest Editor: Tadeusz Robak)]
Current Cancer Drug Targets Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Axin PPI Networks: New Interacting Proteins and New Targets?
Current Topics in Medicinal Chemistry Structural and Functional Organization of miRNAs
Current Pharmacogenomics Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Phosphoproteomics as a Promising Tool for Broadening the Analysis of Clinical Samples and for the Fight Against Cancer Disease
Current Pharmaceutical Analysis